- Home
- EVAX vs XTLB Comparison
EVAX vs XTLB Comparison
Compare EVAX & XTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- XTLB
- Stock Information
- Founded
- EVAX 2008
- XTLB 1993
- Country
- EVAX Denmark
- XTLB Israel
- Employees
- EVAX N/A
- XTLB N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- XTLB Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- XTLB Health Care
- Exchange
- EVAX Nasdaq
- XTLB Nasdaq
- Market Cap
- EVAX 8.7M
- XTLB 7.8M
- IPO Year
- EVAX 2021
- XTLB 2005
- Fundamental
- Price
- EVAX $0.89
- XTLB $1.76
- Analyst Decision
- EVAX Strong Buy
- XTLB
- Analyst Count
- EVAX 2
- XTLB 0
- Target Price
- EVAX $11.00
- XTLB N/A
- AVG Volume (30 Days)
- EVAX 82.5K
- XTLB 12.8K
- Earning Date
- EVAX 10-31-2024
- XTLB 02-20-2025
- Dividend Yield
- EVAX N/A
- XTLB N/A
- EPS Growth
- EVAX N/A
- XTLB N/A
- EPS
- EVAX N/A
- XTLB N/A
- Revenue
- EVAX $3,295,000.00
- XTLB N/A
- Revenue This Year
- EVAX $4,845.21
- XTLB N/A
- Revenue Next Year
- EVAX $30.30
- XTLB N/A
- P/E Ratio
- EVAX N/A
- XTLB N/A
- Revenue Growth
- EVAX N/A
- XTLB N/A
- 52 Week Low
- EVAX $0.85
- XTLB $0.76
- 52 Week High
- EVAX $13.61
- XTLB $4.99
- Technical
- Relative Strength Index (RSI)
- EVAX 21.83
- XTLB 30.57
- Support Level
- EVAX $0.85
- XTLB $1.42
- Resistance Level
- EVAX $0.96
- XTLB $1.83
- Average True Range (ATR)
- EVAX 0.15
- XTLB 0.12
- MACD
- EVAX -0.00
- XTLB -0.04
- Stochastic Oscillator
- EVAX 5.75
- XTLB 3.13
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.